For Walgreens Boots Alliance, Inc. (NASDAQ: WBA), 2024 was a challenging year as it lost market share to competitors and closed several stores amid persistent operational headwinds. It is expected that the retail pharmacy giant’s upcoming earnings will provide cues on its financial health and shed light on the management’s turnaround efforts.
Walgreens hasn’t offered its shareholders anything to cheer about for a long time. The stock has been languishing in a downward spiral and slipped into single-digit territory in recent months. The last closing price is below the long-term average price of $14.46. The stock lost a dismal 65% in 2024. While WBA is expected to regain momentum in the coming weeks, experts are cautious in their recommendations.
On average, analysts following the healthcare company expect revenues of $37.37 billion for the November quarter, representing a 1.81% year-over-year increase. First-quarter net income, adjusted for one-off items, is projected to decline to $0.40 per share from $0.66 per share in the same period last year. The report is expected to be published on Friday, January 10, at 7:00 am ET. The Walgreens leadership expects full-year adjusted earnings per share to be in the range of $1.40 to $1.80.
Walgreens has been facing multiple problems for some time, forcing the management to adopt critical measures to improve operational efficiency and set the stage for a turnaround. The changing retail pharmacy landscape and inflation-related pressure on consumer spending remain the main challenges to the pharmacy business. The company is working to reduce the relatively large debt while implementing its retail strategy and taking steps to enhance margins. In the last fiscal year, it achieved the declared goals of cutting costs by over $1 billion, significantly reducing capital spending, and realizing benefits from working capital initiatives.
“We have over 8,000 stores, of which the majority, approximately 6,000 are profitable. This solid base supports our conviction in a retail pharmacy-led model that is relevant to our consumers, and we intend to invest in these stores over the next several years. Part of the funding for this investment will come from accelerating the closure of underperforming stores. We expect to close approximately 1,200 of those over the next three years and reduce the fixed costs associated with them,” said Walgreens’ CEO Tim Wentworth at the Q4 2024 earnings call.
Walgreens reported a 6% annual growth in total sales to $37.5 billion in the final three months of fiscal 2024, beating estimates. Sales of the US Retail Pharmacy segment, which accounts for 79% of the total, grew by 7%. International sales and US Healthcare sales grew by 3% and 7%, respectively. Fourth-quarter profit, excluding special items, dropped 41% year-over-year to $0.39 per share but topped expectations. On an unadjusted basis, the company reported a net loss of $3.0 billion or $3.48 per share for Q4, compared to a loss of $180 million or $0.21 per share in the year-ago quarter.
On Tuesday, Walgreens’ stock opened below $10 and traded slightly higher in the early hours of the session. The value has more than halved in the past eight months.
The post Walgreens Boots Alliance expected to report mixed Q1 2025 results first appeared on AlphaStreet.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
